Comparing baseline characteristics and treatment between CD5+ vs CD5– MZL
| Characteristic . | CD5+ (n = 64) . | CD5– (n = 137) . | P value∗ . |
|---|---|---|---|
| Age at diagnosis, y | |||
| Median (range) | 64 (24-83) | 64 (22-82) | .716 |
| Q1, Q3 | 51, 71 | 55, 70 | |
| Sex, n | |||
| Male | 35/64 (54.7%) | 71/137 (51.8%) | .763 |
| Female | 29/64 (45.3%) | 66/137 (48.2%) | |
| MZL subtype, n | |||
| NMZL | 13/64 (20.3%) | 20/137 (14.6%) | .379 |
| ENMZL | 38/64 (59.4%) | 95/137 (69.3%) | |
| SMZL | 13/64 (20.3%) | 22/137 (16.1%) | |
| Nodal vs extranodal disease | |||
| Nodal disease | 13/64 (20.3%) | 20/137 (14.6%) | .314 |
| Extranodal disease | 51/64 (79.7%) | 117/137 (85.4%) | |
| Spleen involvement, n | |||
| Yes | 13/51 (25.5%) | 22/117 (18.8%) | .409 |
| No | 38/51 (74.5%) | 95/117 (81.2%) | |
| Stage, n | |||
| I-II | 26/64 (41%) | 78/137 (57%) | .035 |
| III-IV | 38/64 (59%) | 59/137 (43%) | |
| NMZL stage I-II | 3/13 (23%) | 6/20 (30%) | .999 |
| Stage III-IV | 10/13 (77%) | 14/20 (70%) | |
| ENMZL stage I-II | 22/38 (58%) | 71/95 (75%) | .063 |
| Stage III-IV | 16/38 (42%) | 24/95 (25%) | |
| SMZL stage I-II | 1/13 (8%) | 1/22 (5%) | .999 |
| Stage III-IV | 12/13 (92%) | 21/22 (95%) | |
| MALT-IPI score, n | |||
| Low risk (0 points) | 19/58 (32.8%) | 50/121 (41.3%) | .451 |
| Intermediate risk (1 point) | 27/58 (46.6%) | 45/121 (37.2%) | |
| High risk (2-3 points) | 12/58 (20.7%) | 26/121 (21.5%) | |
| Transformation to DLBCL, n | |||
| Yes | 4/58 (6.9%) | 5/121 (4.1%) | .474 |
| No | 54/58 (93.1%) | 5/21 (95.9%) | |
| BM involvement, n | |||
| Yes | 27/40 (67.5%) | 34/72 (47.2%) | .048 |
| No | 13/40 (32.5%) | 38/72 (52.8%) | |
| IGHV mutational status, n | |||
| Mutated | 16/20 (80.0%) | 16/25 (64.0%) | .327 |
| unmutated | 4/20 (20.0%) | 9/25 (36.0%) | |
| LDH > ULN, n | |||
| Yes | 6/8 (10.3%) | 21/121 (17.4%) | .269 |
| No | 52/58 (89.7%) | 100/121 (82.6%) | |
| First-line treatment received, n | |||
| Chemoimmunotherapy | 10/64 (16%) | 26/137 (19%) | .347 |
| R-monotherapy | 16/64 (25%) | 30/137 (22%) | |
| Radiation | 16/64 (25%) | 36/137 (26%) | |
| Excision | 2/64 (3%) | 14/137 (10%) | |
| Never treated | 20/64 (31%) | 31/137 (23 %) |
| Characteristic . | CD5+ (n = 64) . | CD5– (n = 137) . | P value∗ . |
|---|---|---|---|
| Age at diagnosis, y | |||
| Median (range) | 64 (24-83) | 64 (22-82) | .716 |
| Q1, Q3 | 51, 71 | 55, 70 | |
| Sex, n | |||
| Male | 35/64 (54.7%) | 71/137 (51.8%) | .763 |
| Female | 29/64 (45.3%) | 66/137 (48.2%) | |
| MZL subtype, n | |||
| NMZL | 13/64 (20.3%) | 20/137 (14.6%) | .379 |
| ENMZL | 38/64 (59.4%) | 95/137 (69.3%) | |
| SMZL | 13/64 (20.3%) | 22/137 (16.1%) | |
| Nodal vs extranodal disease | |||
| Nodal disease | 13/64 (20.3%) | 20/137 (14.6%) | .314 |
| Extranodal disease | 51/64 (79.7%) | 117/137 (85.4%) | |
| Spleen involvement, n | |||
| Yes | 13/51 (25.5%) | 22/117 (18.8%) | .409 |
| No | 38/51 (74.5%) | 95/117 (81.2%) | |
| Stage, n | |||
| I-II | 26/64 (41%) | 78/137 (57%) | .035 |
| III-IV | 38/64 (59%) | 59/137 (43%) | |
| NMZL stage I-II | 3/13 (23%) | 6/20 (30%) | .999 |
| Stage III-IV | 10/13 (77%) | 14/20 (70%) | |
| ENMZL stage I-II | 22/38 (58%) | 71/95 (75%) | .063 |
| Stage III-IV | 16/38 (42%) | 24/95 (25%) | |
| SMZL stage I-II | 1/13 (8%) | 1/22 (5%) | .999 |
| Stage III-IV | 12/13 (92%) | 21/22 (95%) | |
| MALT-IPI score, n | |||
| Low risk (0 points) | 19/58 (32.8%) | 50/121 (41.3%) | .451 |
| Intermediate risk (1 point) | 27/58 (46.6%) | 45/121 (37.2%) | |
| High risk (2-3 points) | 12/58 (20.7%) | 26/121 (21.5%) | |
| Transformation to DLBCL, n | |||
| Yes | 4/58 (6.9%) | 5/121 (4.1%) | .474 |
| No | 54/58 (93.1%) | 5/21 (95.9%) | |
| BM involvement, n | |||
| Yes | 27/40 (67.5%) | 34/72 (47.2%) | .048 |
| No | 13/40 (32.5%) | 38/72 (52.8%) | |
| IGHV mutational status, n | |||
| Mutated | 16/20 (80.0%) | 16/25 (64.0%) | .327 |
| unmutated | 4/20 (20.0%) | 9/25 (36.0%) | |
| LDH > ULN, n | |||
| Yes | 6/8 (10.3%) | 21/121 (17.4%) | .269 |
| No | 52/58 (89.7%) | 100/121 (82.6%) | |
| First-line treatment received, n | |||
| Chemoimmunotherapy | 10/64 (16%) | 26/137 (19%) | .347 |
| R-monotherapy | 16/64 (25%) | 30/137 (22%) | |
| Radiation | 16/64 (25%) | 36/137 (26%) | |
| Excision | 2/64 (3%) | 14/137 (10%) | |
| Never treated | 20/64 (31%) | 31/137 (23 %) |
ENMZL, extranodal MZL; LDH, lactate dehydrogenase; NMZL, nodal MZL; Q, quartile; R-IPI, revised IPI; R-monotherapy, Rituximab-monotherapy; SMZL, splenic marginal zone lymphoma; UNL, upper normal limit.
Comparison was done using the Wilcoxon rank-sum test for continuous variables and the Fisher exact test for categorical variables.